Roche is paying Elan spin-out Prothena $45m in the near term as part of a new collaboration to develop and commercialize antibodies that target alpha-synuclein. The agreement includes PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease, which is currently in preclinical development and is expected to enter Phase I trials in 2014.
Under the agreement, Prothena will receive an upfront payment and an early clinical milestone totaling $45m. Prothena is also eligible...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
